Integra LifeSciences stockholders elect all director nominees, ratify auditor, approve say-on-pay

Item No. 1: All of the nominees for director of the Board of Directors (the “Board”) of the Company were elected to serve until the Company’s 2024 annual meeting of stockholders or until their respective successors are elected and qualified, by the votes set forth below. Nominees For Against Abstain Broker Non-Vote Keith Bradley 74,622,029 2,199,092 56,101 2,250,376 Shaundra Clay 76,404,281 419,511 53,430 2,250,376 Jan De Witte 75,717,792 1,103,473 55,957 2,250,376 Stuart M. Essig 75,127,004 1,704,299 45,919 2,250,376 Barbara B. Hill 70,176,495 6,647,412 53,315 2,250,376 Renee W. Lo 76,338,362 483,275 55,585 2,250,376 Raymond G. Murphy 74,629,418 2,190,749 57,055 2,250,376 Christian S. Schade 75,358,826 1,460,930 57,466 2,250,376

Item No. 2: The stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the 2023 fiscal year, by the votes set forth below. For Against Abstain Broker Non-Vote 78,368,495 722,305 36,798 0

Item No. 4: The stockholders voted, on an advisory basis, on how frequently future advisory votes on the compensation of the Company’s named executive officers should be held as set forth in the table below. 1 Year 2 Years 3 Years Abstain Broker Non-Vote 75,886,421 3,291 955,372 32,138 2,250,376

Item No. 3: The stockholders approved, on an advisory, non-binding basis, the compensation of the Company’s named executive officers, by the votes set forth below. For Against Abstain Broker Non-Vote 73,644,075 3,183,998 49,149 2,250,376